View Clinical Trial (Medical Research Study)

Cognitive Behavioral Therapy for Insomnia in People With Chronic Obstructive Pulmonary Disease(COPD) - NCT01072292-60612(Clinical Trial 562895)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Chicago
State:  
IL
Zip Code: 60612
Conditions: Insomnia
Purpose: A two-phase research study is being conducted. In Phase 1 of the study, the cognitive behavioral therapy intervention for insomnia was implemented in a small (n = 5) group of people with moderate to severe COPD and insomnia. The intervention was pilot-tested to determine feasibility and acceptability, and the intervention will be refined as needed. In Phase 2 of the study, a two-group randomized controlled study (n = 20) will be conducted to test the effects of the cognitive behavioral therapy for insomnia intervention on the primary outcomes of sleep quality and fatigue and the secondary outcomes of mood and functional performance. It is hypothesized that people with COPD receiving cognitive behavioral therapy for insomnia will demonstrate significant improvements in sleep quality, fatigue, mood and functional performance as compared to people with COPD who receive a wellness program. This research will yield valuable information regarding effective interventions aimed at mitigating problems such as poor sleep quality, fatigue and reduced ability to perform valued daily activities. This information will be used to increase the likelihood of long-term successful outcomes such as the ability to maintain productive roles in society for people with COPD.
Study summary:
Criteria: Inclusion Criteria: - Subjects will have moderate to severe COPD. Severity of COPD will be defined according to the new GOLD standards (moderate IIA (moderate), 50% < FEV1 < 80% predicted; moderate IIB (severe) 30% < FEV1 < 50%). 58 - Insomnia. Insomnia will be defined as difficulty initiating or maintaining sleep, waking up too early or poor quality sleep. 59 - Subjects must be > 45 years of age with no other major health problems - Subjects must be clinically stable at the time of enrollment into the study without major exacerbation of COPD within the previous two months. Exclusion Criteria: - Evidence of restrictive lung disease or asthma. - Evidence of a major sleep disorder other than insomnia (sleep apnea evidenced by apnea/hypopnea index of > 10, periodic limb movement disorder, narcolepsy). - Hypnotic, sedative, anxiolytic or antidepressant use. - Pulse oximetry (SaO2) reading of < 90% at rest. - Pulse oximetry (SaO2) reading of < 85% at night for > 5 minutes. - Significant sleep apnea (apnea/hypopnea index ≥ 10). - .Acute respiratory infection within the previous 2 months. - Class > 2 functional status according to the New York Heart Association. - The presence of a potentially debilitating disease such as cancer, congestive heart failure, kidney disease, liver failure or cirrhosis; evidence of alcohol or drug abuse, musculoskeletal or degenerative nerve disease. - A self-reported current diagnosis of major depression or psychiatric disease or a Hospital Anxiety and Depression Scale (HADS) depression score of > 11. - Currently participating in pulmonary rehabilitation.
Study is available at: University of Illinois at Chicago
Chicago, IL 60612
United States

Primary Contact:
Mary C Kapella, PhD
Email: mkapel1@uic.edu
Phone: 312-355-3150
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.